# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $6...
EF Hutton analyst Jason Kolbert initiates coverage on Enlivex Therapeutics (NASDAQ:ENLV) with a Buy rating and announces Pri...
First patient dosed with AllocetraTM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and lowers the pr...
First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and ha...